Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 51, 2009, Pages 21608-21613

  Jura, Natalia ^a   Shan, Yibing ^b   Cao, Xiaoxian ^a   Shaw, David E ^b,c   Kuriyan, John ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b D E SHAW RESEARCH   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

EGFR; Human epidermal growth factor receptor 3; Human epidermal growth factor receptor4; Receptor oligomerization

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; ENZYME BINDING; EVOLUTIONARY HOMOLOGY; HYDROPHOBICITY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; BIOCATALYSIS; CRYSTALLOGRAPHY, X-RAY; DIMERIZATION; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 76049128717     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912101106     Document Type: Article

References (39)

1. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
2. Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL, 3rd (1994) Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 91:8132-8136.
3. Wieduwilt MJ, Moasser MM (2008) The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cell Mol Life Sci 65:1566-1584.
4. Baselga J, Swain SM (2009) Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9:463-475.
5. Soltoff SP, Carraway KL, 3rd, Prigent SA, Gullick WG, Cantley LC (1994) ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14:3550-3558.
6. Sergina NV, et al. (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441.
7. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149.
8. Jeffrey PD, et al. (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376:313-320.
9. Sierke SL, Cheng K, Kim HH, Koland JG (1997) Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem J 322:757-763.
10. Prigent SA, Gullick WJ (1994) Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13:2831-2841.
11. Wallasch C, et al. (1995) Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14:4267-4275.
12. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912-1934.
13. Mukherjee K, et al. (2008) CASK functions as a Mg2+-independent neurexin kinase. Cell 133:328-339.
14. Scheeff ED, Eswaran J, Bunkoczi G, Knapp S, Manning G (2009) Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17:128-138.
15. De Bondt HL, et al. (1993) Crystal structure of cyclin-dependent kinase 2. Nature 363:595-602.
16. Sicheri F, Moarefi I, Kuriyan J (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385:602-609.
17. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC (1999) Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3:629-638.
18. Deindl S, et al. (2007) Structural basis for the inhibition of tyrosine kinase activity of ZAP-70. Cell 129:735-746.
19. Wood ER, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659.
20. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109:275-282.
21. Jura N, et al. (2009) Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137:1293-1307.
22. Red Brewer M, et al. (2009) The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 34:641-651.
23. Cho HS, Leahy DJ (2002) Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297:1330-1333.
24. Levinson NM, et al. (2006) A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 4:e144.
25. Shan Y, et al. (2009) A conserved protonation-dependent switch controls drug binding in the Abl kinase. Proc Natl Acad Sci USA 106:139-144.
26. Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. J Mol Graphics 14:33-38.
27. Qiu C, et al. (2008) Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure 16:460-467.
28. Schymkowitz J, et al. (2005) The FoldX web server: An online force field. Nucleic Acids Res 33(Web Server issue):W382-W388.
29. Zhang X, et al. (2007) Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface. Nature 450:741-744.
30. Landgraf R, Eisenberg D (2000) Heregulin reverses the oligomerization of HER3. Biochemistry 39:8503-8511.
31. Kani K, Park E, Landgraf R (2005) The extracellular domains of ErbB3 retain high ligand binding affinity at endosome pH and in the locked conformation. Biochemistry 44:15842-15857.
32. Berger MB, Mendrola JM, Lemmon MA (2004) ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 569:332-336.
33. Stein RA, Staros JV (2006) Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evol Biol 6:79.
34. Barnes NL, et al. (2005) Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res 11:2163-2168.
35. Kew TY, et al. (2000) c-erbB-4 protein expression in human breast cancer. Br J Cancer 82:1163-1170.
36. Otwinowski Z, Minor W (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
37. Adams PD, et al. (2002) PHENIX: Building new software for automated crystallographic structure determination. Acta Crystallogr D 58(Pt 11):1948-1954.
38. Jones TA, Zou JY, Cowan SW, Kjeldgaard M (1991) Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A 47(Pt 2):110-119.
39. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. Acta Crystallogr D 60(Pt 12 Pt 1):2126-2132.